Literature DB >> 5479859

Studies on epoxide formation from (2S,3S)-threitol 1,4-bismethanesulfonate. The preparation and biological activity of (2S,3S)-1,2-epoxy-3,4-butanediol 4-methanesulfonate.

P W Feit, N Rastrup-Andersen, R Matagne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 5479859     DOI： 10.1021/jm00300a034

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  15 in total

1.  Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma: a phase II study.

Authors:  Wolfgang Wick; Mirjam Hermisson; Rolf D Kortmann; Wilhelm M Küker; Frank Duffner; Johannes Dichgans; Michael Bamberg; Michael Weller
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

2.  Modelling of neutrophil dynamics in children receiving busulfan or treosulfan for haematopoietic stem cell transplant conditioning.

Authors:  Belén P Solans; Robert Chiesa; Bilyana Doncheva; Helen Prunty; Paul Veys; Iñaki F Trocóniz; Joseph F Standing
Journal:  Br J Clin Pharmacol       Date:  2020-03-03       Impact factor: 4.335

3.  Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.

Authors:  Eneida R Nemecek; Katherine A Guthrie; Mohamed L Sorror; Brent L Wood; Kristine C Doney; Ralf A Hilger; Bart L Scott; Tibor J Kovacsovics; Richard T Maziarz; Ann E Woolfrey; Antonio Bedalov; Jean E Sanders; John M Pagel; Eileen J Sickle; Robert Witherspoon; Mary E Flowers; Frederick R Appelbaum; H Joachim Deeg
Journal:  Biol Blood Marrow Transplant       Date:  2010-05-26       Impact factor: 5.742

4.  Treosulfan chemotherapy for recurrent malignant glioma.

Authors:  F Schmidt; W Wick; U Herrlinger; J Dichgans; M Weller
Journal:  J Neurooncol       Date:  2000-09       Impact factor: 4.130

5.  Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium.

Authors:  Eneida R Nemecek; Ralf A Hilger; Alexia Adams; Bronwen E Shaw; Deidre Kiefer; Jennifer Le-Rademacher; John E Levine; Gregory Yanik; Wing Leung; Julie-An Talano; Paul Haut; David Delgado; Neena Kapoor; Aleksandra Petrovic; Roberta Adams; Rabi Hanna; Hemalatha Rangarajan; Jignesh Dalal; Joseph Chewning; Michael R Verneris; Stacy Epstein; Lauri Burroughs; Evelio D Perez-Albuerne; Michael A Pulsipher; Colleen Delaney
Journal:  Biol Blood Marrow Transplant       Date:  2018-05-09       Impact factor: 5.742

6.  Antitumor activity of treosulfan in human lung carcinomas.

Authors:  P Köpf-Maier; G Sass
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

7.  Pharmacokinetics and Pharmacodynamics of Treosulfan in Patients With Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Ezhilpavai Mohanan; John C Panetta; Kavitha M Lakshmi; Eunice S Edison; Anu Korula; Fouzia Na; Aby Abraham; Auro Viswabandya; Biju George; Vikram Mathews; Alok Srivastava; Poonkuzhali Balasubramanian
Journal:  Clin Pharmacol Ther       Date:  2018-01-17       Impact factor: 6.875

8.  Airborne cytotoxicity in the DiSC assay caused by solutions of treosulfan but not busulphan.

Authors:  A G Bosanquet; A R Burlton
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

Review 9.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. General considerations, the nitrosoureas and alkylating agents.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 10.  Treosulfan-based conditioning for inborn errors of immunity.

Authors:  Mary A Slatter; Andrew R Gennery
Journal:  Ther Adv Hematol       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.